An Alternative Route — with Partners Collaborating on R&D, Licensing, Marketing: Less Risk and Less Margin
‘We’ve got four drugs on the market since 1985, being sold by a licensee. That, combined with reworking our commercial strategy, enabled us to begin building a very substantial revenue stream, from these drugs which are being sold by licensees in the form of royalties, which are going to permit us now to probably build revenues for the company over the next several years to well beyond the $100m level. Our principal licensees, Abbott Laboratories and Ortho Diagnostics, are gaining an increasingly large piece of the $250m world diagnostic market.
KeywordsBurner Hepatitis Carbide Europe Income
Unable to display preview. Download preview PDF.